NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

An Open-Label, Multi Center, Clinical Trial: External Continuous Subcutaneous Infusion of Insulin Using Insulin Aspart (NovoLog®) in Subjects With Type 1 and Insulin Requiring Type 2 Diabetes

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00095446

Enrollment

513

Registered

2004-11-05

Start date

2004-07-31

Completion date

2005-03-31

Last updated

2017-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Keywords

Diabetes Mellitus, Diabetes

Brief summary

This trial is conducted in the United States of America (USA). The aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in standard clinical practice.

Interventions

DRUGinsulin aspart

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* People with Type I or Type II Diabetes * 18 Years or Older.

Design outcomes

Primary

Measure	Time frame
Treatment satisfaction with insulin pump therapy	—

Secondary

Measure	Time frame
body weight	—
Insulin dose	—
Overall glycemic control	—
number and types of infusion sets used.	—
infusion set in-use times	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026